Aspergillosis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Pfizer, Pulmocide, Astellas Pharma, Nektar Therapeutics, Regeneron Pharmaceuticals, Sanofi and Others

Aspergillosis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Pfizer, Pulmocide, Astellas Pharma, Nektar Therapeutics, Regeneron Pharmaceuticals, Sanofi and Others

Aspergillosis Pipeline

Aspergillosis is an infection caused by Aspergillus, a common mold (a type of fungus) that lives indoors and outdoors. Most people breathe in Aspergillus spores every day without getting sick. However, people with weakened immune systems or lung diseases are at a higher risk of developing health problems due to Aspergillus. The types of health problems caused by Aspergillus include allergic reactions, lung infections, and infections in other organs.

 

DelveInsight’s, Aspergillosis Pipeline Insights, 2021,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Aspergillosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

 

Get free sample page @ https://www.delveinsight.com/sample-request/aspergillosis-pipeline-insight

 

Some of Aspergillosis Companies are:

  • Pulmocide
  • Astellas Pharma
  • Nektar Therapeutics
  • Pulmatrix
  • F2G
  • Pfizer
  • Cellix Bio
  • Regeneron Pharmaceuticals/Sanofi
  • Scynexis
  • Matinas BioPharma
  • TFF Pharmaceuticals
  • And Many Others

Get free sample page @ https://www.delveinsight.com/sample-request/aspergillosis-pipeline-insight

 

DelveInsight’s report covers around 50+ products under different phases of clinical development like

  • Late-stage products (Phase II and Phase II/III)
  • Mid-stage products (Phase II and Phase II/III)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Some of Aspergillosis Therapies:

  • PC 945
  • Itraconazole inhaled
  • Isavuconazole
  • Amphotericin B inhalation
  • Olorofim
  • Anidulafungin/voriconazole
  • CLX IFN 59
  • Dupilumab
  • Ibrexafungerp:
  • MAT2203
  • TFF VORI

Get free sample page @ https://www.delveinsight.com/sample-request/aspergillosis-pipeline-insight

 

Table of Contents:

Introduction

Executive Summary

Aspergillosis: Overview

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

Aspergillosis – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

• Aspergillosis companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Aspergillosis Collaboration Deals

Late Stage Products (Phase III)

• Comparative Analysis

Dupilumab: Regeneron Pharmaceuticals/Sanofi

Mid Stage Products (Phase II)

• Comparative Analysis

Ibrexafungerp: Scynexis

PC945: Pulmocide

Early Stage Products (Phase I)

• Comparative Analysis

TFF VORI: TFF Pharmaceuticals

Pre-clinical and Discovery Stage Products

• Comparative Analysis

MAT2203: Matinas BioPharma

Inactive Products

• Comparative Analysis

Aspergillosis Key Companies

Aspergillosis Key Products

Aspergillosis- Unmet Needs

Aspergillosis- Market Drivers and Barriers

Aspergillosis- Future Perspectives and Conclusion

Aspergillosis Analyst Views

Aspergillosis Key Companies

Appendix

 

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/aspergillosis-pipeline-insight